{"id":"cyclophosphamide-or-azathioprine","safety":{"commonSideEffects":[{"rate":"10-30%","effect":"Myelosuppression"},{"rate":"20-50%","effect":"Nausea and vomiting"},{"rate":"10-30%","effect":"Hair loss"},{"rate":"10-30%","effect":"Fatigue"},{"rate":"5-20%","effect":"Infection"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"They work by attaching an alkyl group to the DNA of cancer cells, which prevents the cells from replicating. This leads to cell death and ultimately, tumor shrinkage. Both drugs are used in chemotherapy regimens to treat various types of cancer.","oneSentence":"Cyclophosphamide and azathioprine are alkylating agents that interfere with DNA replication, thereby inhibiting cancer cell growth.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:08:18.126Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of certain types of leukemia, lymphoma, and other cancers"},{"name":"Prevention of organ transplant rejection"}]},"trialDetails":[{"nctId":"NCT07077486","phase":"PHASE4","title":"Effects of Telitacicept vs Cyclophosphamide on Lupus Related Interstitial Lung Disease","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-08-25","conditions":"Lupus or SLE, Interstitial Lung Disease, Systemic Lupus Erythematosus","enrollment":100},{"nctId":"NCT02807103","phase":"PHASE3","title":"Rituximab in Eosinophilic Granulomatosis With Polyangiitis","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2016-12-05","conditions":"Eosinophilic Granulomatosis With Polyangiitis (EGPA)","enrollment":107},{"nctId":"NCT04745728","phase":"PHASE3","title":"Different Immunosuppressive Treatment in iMN","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2021-04-14","conditions":"Idiopathic Membranous Nephropathy","enrollment":200},{"nctId":"NCT07168161","phase":"PHASE3","title":"BDB-001 Phase III Trial in ANCA-Associated Vasculitis","status":"RECRUITING","sponsor":"Staidson (Beijing) Biopharmaceuticals Co., Ltd","startDate":"2025-11-10","conditions":"ANCA Associated Vasculitis (AAV)","enrollment":300},{"nctId":"NCT05998759","phase":"PHASE2","title":"Telitacicept for the Treatment of Connective Tissue Disease-associated Thrombocytopenia","status":"RECRUITING","sponsor":"Beijing Hospital","startDate":"2023-12-02","conditions":"Connective Tissue Diseases, Thrombocytopenia","enrollment":296},{"nctId":"NCT02994927","phase":"PHASE3","title":"A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis","status":"COMPLETED","sponsor":"Amgen","startDate":"2017-03-15","conditions":"ANCA-Associated Vasculitis","enrollment":331},{"nctId":"NCT06226662","phase":"PHASE2","title":"Study of NM8074 in Patients with Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis (AAV)","status":"NOT_YET_RECRUITING","sponsor":"NovelMed Therapeutics","startDate":"2026-06","conditions":"Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis","enrollment":12},{"nctId":"NCT00103792","phase":"PHASE3","title":"Mycophenolate Mofetil for Treatment of Relapses of Wegener's Disease or Microscopic Polyangiitis (MPA)","status":"COMPLETED","sponsor":"University Medical Center Groningen","startDate":"2004-12","conditions":"Wegener's Granulomatosis, Vasculitis","enrollment":84},{"nctId":"NCT05247203","phase":"PHASE1","title":"Telitacicept Study in Chinese Subjects With Systemic Lupus Erythematosus","status":"COMPLETED","sponsor":"RemeGen Co., Ltd.","startDate":"2022-05-11","conditions":"Systemic Lupus Erythematosus","enrollment":92},{"nctId":"NCT04082416","phase":"PHASE3","title":"Study of Recombinant Human B Lymphocyte(RC18) Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus(SLE)","status":"COMPLETED","sponsor":"RemeGen Co., Ltd.","startDate":"2019-10-16","conditions":"Systemic Lupus Erythematosus","enrollment":335},{"nctId":"NCT04101578","phase":"","title":"Clinical Prognosis and Progression of Myasthenia Gravis Patients","status":"UNKNOWN","sponsor":"Da, Yuwei, M.D.","startDate":"2017-02-08","conditions":"Myasthenia Gravis","enrollment":2000},{"nctId":"NCT01639339","phase":"PHASE3","title":"Efficacy and Safety of Belimumab in Patients With Active Lupus Nephritis","status":"COMPLETED","sponsor":"Human Genome Sciences Inc., a GSK Company","startDate":"2012-07-12","conditions":"Lupus Nephritis","enrollment":448},{"nctId":"NCT02297126","phase":"NA","title":"A Prospective Trial to Assess Cost and Clinical Outcomes of a Clinical Pharmacogenomic Program","status":"COMPLETED","sponsor":"Indiana University","startDate":"2015-03","conditions":"Adverse Drug Reaction","enrollment":4465},{"nctId":"NCT00626197","phase":"PHASE3","title":"A Study to Evaluate Ocrelizumab in Patients With Nephritis Due to Systemic Lupus Erythematosus (BELONG)","status":"TERMINATED","sponsor":"Genentech, Inc.","startDate":"2008-02-15","conditions":"Lupus Nephritis, Systemic Lupus Erythematosus","enrollment":381},{"nctId":"NCT02885610","phase":"PHASE2","title":"Study of RC18 Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus(SLE)","status":"COMPLETED","sponsor":"RemeGen Co., Ltd.","startDate":"2015-12","conditions":"Systemic Lupus Erythematosus","enrollment":249},{"nctId":"NCT03791827","phase":"","title":"Multicenter Registry of Pediatric Lupus Nephritis in China","status":"UNKNOWN","sponsor":"Xiqiang Dang","startDate":"2018-12-01","conditions":"Lupus Nephritis, Children, Steroid","enrollment":1200},{"nctId":"NCT03886233","phase":"","title":"Treatment Outcome of Uveitis in Autoimmune Diseases","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2019-03","conditions":"Autoimmune Uveitis","enrollment":1},{"nctId":"NCT03468972","phase":"PHASE4","title":"Effect of Immunosuppression in IgA Nephropathy","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2019-03","conditions":"Biopsy-proven IgA Nephropathy","enrollment":174},{"nctId":"NCT02936375","phase":"PHASE2","title":"The Iguratimod Effect on Lupus Nephritis (IGeLU)","status":"UNKNOWN","sponsor":"RenJi Hospital","startDate":"2017-09-07","conditions":"Lupus Nephritis","enrollment":120},{"nctId":"NCT02294344","phase":"NA","title":"The Clinical Efficacy of DFPP in Patients With AAGN","status":"TERMINATED","sponsor":"Zhi-Hong Liu, M.D.","startDate":"2014-06","conditions":"Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis","enrollment":14},{"nctId":"NCT02728271","phase":"EARLY_PHASE1","title":"Immuno-ablation With Chemoimmunoradiation and Autologous Stem Cell Transplant for Churg-Strauss Syndrome","status":"TERMINATED","sponsor":"Mounzer Agha","startDate":"2016-04","conditions":"Churg-Strauss Syndrome","enrollment":1},{"nctId":"NCT00152113","phase":"PHASE1","title":"Haploidentical Stem Cell Transplant for Patients With Sickle Cell Disease and Prior Stroke or Abnormal Transcranial Ultrasound","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2005-04","conditions":"Sickle Cell Disease","enrollment":5},{"nctId":"NCT00104299","phase":"PHASE2, PHASE3","title":"Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2005-01","conditions":"Vasculitis, Wegener's Granulomatosis, Microscopic Polyangiitis","enrollment":197},{"nctId":"NCT01275287","phase":"PHASE2","title":"Targeting Complement Activation in Antineutrophil Cytoplasmic Autoantibodies (ANCA)-Vasculitis - Eculizumab","status":"WITHDRAWN","sponsor":"University of North Carolina, Chapel Hill","startDate":"2011-05","conditions":"Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis","enrollment":""},{"nctId":"NCT01834157","phase":"","title":"Improvement of Hand Dysfunction by Arthritis in Systemic Sclerosis","status":"UNKNOWN","sponsor":"Prof. Laszlo Czirjak","startDate":"2013-04","conditions":"Systemic Sclerosis, Arthritis","enrollment":160},{"nctId":"NCT01446211","phase":"PHASE3","title":"Clinical Study Comparing the New Immunosuppressive Drug Gusperimus With the Conventional Treatment in Wegener's Granulomatosis","status":"TERMINATED","sponsor":"Nordic Pharma SAS","startDate":"2011-11","conditions":"Wegeners Granulomatosis","enrollment":4},{"nctId":"NCT00425438","phase":"PHASE3","title":"A Study of CellCept (Mycophenolate Mofetil) in Patients With Lupus Nephritis.","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2007-03","conditions":"Lupus Nephritis","enrollment":52},{"nctId":"NCT02135380","phase":"PHASE1, PHASE2","title":"Evaluate Safety and Efficacy of Intravenous Autologous ADMSc for Treatment of Idiopathic Pulmonary Fibrosis","status":"UNKNOWN","sponsor":"Kasiak Research Pvt. Ltd.","startDate":"2014-08","conditions":"Idiopathic Pulmonary Fibrosis","enrollment":60},{"nctId":"NCT01914770","phase":"","title":"Effectiveness of Belimumab Treatment in a Subpopulation of Systemic Lupus Erythematosus (SLE) Patients: a Pooled Analysis of BLISS-52 and BLISS-76","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-07","conditions":"Systemic Lupus Erythematosus","enrollment":1016},{"nctId":"NCT00556192","phase":"PHASE2","title":"Can Targeted Elimination of B-cell Depletion Therapy and/or Combination Therapy on Systemic Lupus Erythematosus","status":"COMPLETED","sponsor":"Chinese University of Hong Kong","startDate":"2006-06","conditions":"Systemic Lupus Erythematosus","enrollment":20},{"nctId":"NCT00377637","phase":"PHASE3","title":"A Study of Mycophenolate Mofetil (CellCept) in Management of Patients With Lupus Nephritis.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2005-07","conditions":"Lupus Nephritis","enrollment":370},{"nctId":"NCT00307671","phase":"PHASE4","title":"Treatment of Necrotizing Vasculitides for Patients Older Than 65 Years","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2005-07","conditions":"Vasculitis, Wegener's Granulomatosis, Microscopic Polyangiitis","enrollment":108},{"nctId":"NCT01207297","phase":"PHASE1","title":"Tacrolimus Versus Cyclophosphamide as Treatment for Lupus Nephritis","status":"COMPLETED","sponsor":"Zhejiang University","startDate":"2003-03","conditions":"SLE, Lupus Nephritis, Renal Insufficiency","enrollment":40},{"nctId":"NCT00615173","phase":"PHASE3","title":"Prospective, Randomized, Multicenter, Control Study to Assess the Efficacy and Safety of Tacrolimus in Induction and Maintenance Phase Treatment in Lupus Nephritis","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2006-07","conditions":"Kidney Diseases, Lupus Nephritis, Tacrolimus","enrollment":81},{"nctId":"NCT00753103","phase":"PHASE2","title":"Anti-Cytokine Therapy for Vasculitis","status":"COMPLETED","sponsor":"University Hospital Birmingham NHS Foundation Trust","startDate":"2003-01","conditions":"Wegener's Granulomatosis, Renal Limited Vasculitis, Microscopic Polyangiitis","enrollment":37},{"nctId":"NCT00349674","phase":"PHASE3","title":"WEGENT - Comparison of Methotrexate or Azathioprine as Maintenance Therapy for ANCA-Associated Vasculitides","status":"UNKNOWN","sponsor":"Hospices Civils de Lyon","startDate":"1999-01","conditions":"Systemic Wegener's Granulomatosis","enrollment":126}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":102276,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"cyclophosphamide or azathioprine","genericName":"cyclophosphamide or azathioprine","companyName":"Sun Yat-sen University","companyId":"sun-yat-sen-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cyclophosphamide and azathioprine are alkylating agents that interfere with DNA replication, thereby inhibiting cancer cell growth. Used for Treatment of certain types of leukemia, lymphoma, and other cancers, Prevention of organ transplant rejection.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}